NCT01602393View on ClinicalTrials.gov

Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Alzheimer's Disease
Interventions
DRUG

CHF 5074 1x

oral tablet, 1x, once a day in the morning for 48 weeks

DRUG

CHF 5074 2x

oral tablet, 2x, once a day in the morning for 48 weeks

DRUG

CHF 5074 3x

oral tablet, 3x, once a day in the morning for 48 weeks

Trial Locations (5)

78757

Senior Adults Specialty Research, Austin

07724

Memory Enhancement Center of America, Inc., Eatontown

08831

Memory Center of New Jersey, Inc., Monroe Twp

08755

Memory Enhancement Center of NJ, Inc., Toms River

Unknown

Osp. Niguarda Ca'Granda, Dip. Di Neuroscienze, Milan

All Listed Sponsors
lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT01602393 - Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase | Biotech Hunter | Biotech Hunter